Non-invasive hepatic biomarkers (ELF and CK18) in people with type 2 diabetes: The Edinburgh type 2 diabetes study

Liver International

Volumn 34, Issue 8, 2014, Pages 1267-1277

  Morling, Joanne R ^a   Fallowfield, Jonathan A ^b   Williamson, Rachel M ^c   Nee, Lisa D ^c   Jackson, Andrew P ^d   Glancy, Stephen ^c   Reynolds, Rebecca M ^a   Hayes, Peter C ^e   Guha, Indra N ^d   Strachan, Mark W J ^c   Price, Jackie F ^a  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

^b UNIVERSITY OF EDINBURGH   (United Kingdom)

^c WESTERN GENERAL HOSPITAL   (United Kingdom)

^d UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^e ROYAL INFIRMARY OF EDINBURGH   (United Kingdom)

Author keywords

Cytokeratin 18; Enhanced liver fibrosis score; Fatty liver disease; Non invasive hepatic biomarkers; Type 2 diabetes mellitus

Indexed keywords

CYTOKERATIN 18; BIOLOGICAL MARKER;

ADULT; AGED; ARTICLE; CHRONIC LIVER DISEASE; CLINICAL ASSESSMENT; COHORT ANALYSIS; DISEASE ASSOCIATION; ECHOGRAPHY; ENHANCED LIVER FIBROSIS SCORE; FEMALE; HUMAN; INSULIN TREATMENT; LIVER; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; NON INVASIVE MEASUREMENT; PHYSICAL EXAMINATION; PROSPECTIVE STUDY; RISK FACTOR; SCORING SYSTEM; SOUTH KOREA; BLOOD; COMPLICATION; DIABETES MELLITUS, TYPE 2; FATTY LIVER; LIVER CIRRHOSIS; MIDDLE AGED; PATHOLOGY; UNITED KINGDOM;

AGED; BIOLOGICAL MARKERS; COHORT STUDIES; DIABETES MELLITUS, TYPE 2; FATTY LIVER; HUMANS; KERATIN-18; LIVER CIRRHOSIS; MIDDLE AGED; RISK FACTORS; SCOTLAND;

EID: 84905731748     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/liv.12385     Document Type: Article

References (43)

1. Ford ES, Giles WH, Mokdad AH. Increasing prevalence of the metabolic syndrome among U.S. adults. Diabetes Care 2004; 27: 2444-9.
2. Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology 2012; 55: 2005-23.
3. Charlton MR, Burns JM, Pedersen RA, et al. Frequency and outcomes of liver transplantation for nonalcoholic steatohepatitis in the United States. Gastroenterology 2011; 141: 1249-53.
4. Baumeister SE, Völzke H, Marschall P, et al. Impact of fatty liver disease on health care utilization and costs in a general population: a 5-year observation. Gastroenterology 2008; 134: 85-94.
5. Calori G, Lattuada G, Ragogna F, et al. Fatty liver index and mortality: the Cremona study in the 15th year of follow-up. Hepatology 2011; 54: 145-52.
6. de Marco R, Locatelli F, Zoppini G, et al. Cause-specific mortality in type 2 diabetes The Verona Diabetes Study. Diabetes Care 1999; 22: 756-61.
7. Gilmore IT, Burroughs A, Murray-Lyon IM, et al. Indications, methods, and outcomes of percutaneous liver biopsy in England and Wales: an audit by the British Society of Gastroenterology and the Royal College of Physicians of London. Gut 1995; 36: 437-41.
8. Ratziu V, Charlotte F, Heurtier A, et al. Sampling variability of liver biopsy in nonalcoholic fatty liver disease. Gastroenterology 2005; 128: 1898-906.
9. Bantel H, Lügering A, Heidemann J, et al. Detection of apoptotic caspase activation in sera from patients with chronic HCV infection is associated with fibrotic liver injury. Hepatology 2004; 40: 1078-87.
10. Wieckowska A, Zein NN, Yerian LM, et al. In vivo assessment of liver cell apoptosis as a novel biomarker of disease severity in nonalcoholic fatty liver disease. Hepatology 2006; 44: 27-33.
11. Feldstein AE, Wieckowska A, Lopez AR, et al. Cytokeratin-18 fragment levels as noninvasive biomarkers for nonalcoholic steatohepatitis: a multicenter validation study. Hepatology 2009; 50: 1072-8.
12. Yilmaz Y, Dolar E, Ulukaya E, et al. Soluble forms of extracellular cytokeratin 18 may differentiate simple steatosis from nonalcoholic steatohepatitis. World J Gastroenterol 2007; 13: 837-44.
13. Yoo EJ, Kim BK, Kim SU, et al. Normal enhanced liver fibrosis (ELF) values in apparently healthy subjects undergoing a health check-up and in living liver donors in South Korea. Liver International 2013; 33: 706-13.
14. Leite NC, Salles GF, Araujo ALE, Villela-Nogueira CA, Cardoso CRL. Prevalence and associated factors of non-alcoholic fatty liver disease in patients with type-2 diabetes mellitus. Liver International 2009; 29: 113-9.
15. Leite NC, Villela-Nogueira CA, Pannain VLN, et al. Histopathological stages of nonalcoholic fatty liver disease in type 2 diabetes: prevalences and correlated factors. Liver International 2011; 31: 700-6.
16. Guha IN, Parkes J, Roderick P, et al. Noninvasive markers of fibrosis in nonalcoholic fatty liver disease: validating the European liver fibrosis panel and exploring simple markers.[see comment]. Hepatology 2008; 47: 455-60.
17. Price J, Reynolds R, Mitchell R, et al. The Edinburgh type 2 diabetes study: study protocol. BMC Endocrine Disorders 2008; 8: 18.
18. Marioni RE, Strachan MWJ, Reynolds RM, et al. Association between raised inflammatory markers and cognitive decline in elderly people with Type 2 diabetes: the Edinburgh type 2 diabetes study. Diabetes 2010; 59: 710-3.
19. Williamson RM, Price JF, Glancy S, et al. Prevalence of and risk factors for hepatic steatosis and nonalcoholic fatty liver disease in people with type 2 diabetes: the Edinburgh type 2 diabetes study. Diabetes Care 2011; 34: 1139-44.
20. Williamson RM, Price JF, Hayes PC, et al. Prevalence and markers of advanced liver disease in type 2 diabetes. QJM 2012; 105: 425-32.
21. Bush K, Kivlahan DR, Mcdonell MB, Fihn SD, Ka B. The audit alcohol consumption questions (audit-c): an effective brief screening test for problem drinking. Arch Intern Med 1998; 158: 1789-95.
22. Williamson RM, Perry E, Glancy S, et al. The use of ultrasound to diagnose hepatic steatosis in type 2 diabetes: intra- and interobserver variability and comparison with magnetic resonance spectroscopy. Clin Radiol 2011; 66: 434-9.
23. Sanyal AJ. AGA technical review on nonalcoholic fatty liver disease. Gastroenterology 2002; 123: 1705-25.
24. Saadeh S, Younossi ZM, Remer EM, et al. The utility of radiological imaging in nonalcoholic fatty liver disease. Gastroenterology 2002; 123: 745-50.
25. Joseph AE, Saverymuttu SH, Al-Sam S, Cook MG, Maxwell JD. Comparison of liver histology with ultrasonography in assessing diffuse parenchymal liver disease. Clin Radiol 1991; 43: 26-31.
26. Royal College of Physicians. Inquiry on alcohol guideliines. London: Royal College of Physicians of London, 2011.
27. Angulo P. Nonalcoholic fatty liver disease. N Engl J Med 2002; 346: 1221-31.
28. Alvarez F, Berg PA, Bianchi FB, et al. International autoimmune hepatitis group report: review of criteria for diagnosis of autoimmune hepatitis. J Hepatol 1999; 31: 929-38.
29. White IR, Royston P, Wood AM. Multiple imputation using chained equations: issues and guidance for practice. Stat Med 2011; 30: 377-99.
30. Agarwal AK, Jain V, Singla S, et al. Prevalence of non-alcoholic fatty liver disease and its correlation with coronary risk factors in patients with type 2 diabetes. J Assoc Physicians India 2011; 59: 351-4.
31. Prashanth M, Ganesh HK, Vima MV, et al. Prevalence of nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus.[see comment]. J Assoc Physicians India 2009; 57: 205-10.
32. Targher G, Bertolini L, Padovani R, et al. Prevalence of nonalcoholic fatty liver disease and its association with cardiovascular disease among type 2 diabetic Diabetes Care 2007; 30: 1212-8.
33. Haima P Quantitative determination of caspase-cleaved keratin 18 (ccK18), an apoptosis specific biomarker for asessment of disease activity in patients with chronic liver disease. TecoMedical Group/Peviva: Bromma, Sweden, 2011.
34. Argo CK, Northup PG, Al-Osaimi AMS, Caldwell SH. Systematic review of risk factors for fibrosis progression in non-alcoholic steatohepatitis. J Hepatol 2009; 51: 371-9.
35. Lindqvist U, Laurent TC. Serum hyaluronan and aminoterminal propeptide of type III procollagen: variation with age. Scand J Clin Lab Invest 1992; 52: 613-21.
36. Day CP, James OFW. Steatohepatitis: a tale of two "hits"? Gastroenterology 1998; 114: 842-5.
37. Van Der Poorten D, Milner K-L, Hui J, et al. Visceral fat: a key mediator of steatohepatitis in metabolic liver disease. Hepatology 2008; 48: 449-57.
38. Browning JD, Horton JD. Molecular mediators of hepatic steatosis and liver injury. J Clin Investig 2004; 114: 147-52.
39. Tilg H, Moschen AR. Evolution of inflammation in nonalcoholic fatty liver disease: the multiple parallel hits hypothesis. Hepatology 2010; 52: 1836-46.
40. Wanless I, Shiota K. The pathogenesis of nonalcoholic steatohepatitis and other fatty liver diseases: a four-step model including the role of lipid release and hepatic venular obstruction in the progression to cirrhosis. Semin Liver Dis 2004; 24: 99-106.
41. Sanyal AJ, Campbell-Sargent C, Mirshahi F, et al. Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities. Gastroenterology 2001; 120: 1183-92.
42. Kashyap SR, Diab DL, Baker AR, et al. Triglyceride levels and not adipokine concentrations are closely related to severity of nonalcoholic fatty liver disease in an obesity surgery cohort. Obesity 2009; 17: 1696-701.
43. Ginsberg HN. Is the slippery slope from steatosis to steatohepatitis paved with triglyceride or cholesterol? Cell Metab 2006; 4: 179-81.